Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
186
|
September 4, 2023
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
222
|
August 29, 2023
|
Individual response
|
|
234
|
30240
|
August 21, 2023
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
30
|
1440
|
August 15, 2023
|
Design of Experiments in Economics vs Medicine: a Decision Theory POV
|
|
6
|
897
|
July 27, 2023
|
Inferences from summary data - without seeing the data for a Cox PH model, do chi square tests tell us anything?
|
|
5
|
113
|
July 24, 2023
|
Case-control study with and corresponding subgroup
|
|
2
|
200
|
July 20, 2023
|
Impact of Model Intercepts on Ordinal Logistic Regression Outcome
|
|
7
|
261
|
June 22, 2023
|
P values and small sample size
|
|
6
|
391
|
June 20, 2023
|
Minimum PPV/NPV values to reach positive net benefit and net benefit avoided
|
|
10
|
703
|
June 12, 2023
|
Outlier detection
|
|
3
|
609
|
May 11, 2023
|
HR really close to 1 but significant - how to interpret and report?
|
|
9
|
708
|
April 25, 2023
|
FDA "Bad Habits"
|
|
7
|
1394
|
March 4, 2023
|
Advice regarding a Directed Acyclic Graph and further analysis Plan
|
|
7
|
705
|
January 22, 2023
|
Table 2 Fallacy?: Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
|
|
23
|
1814
|
January 4, 2023
|
R package to present summary results from many different mixed effects models
|
|
3
|
551
|
December 28, 2022
|
Interpretation of subject-specific effect in a cross-over study
|
|
5
|
3122
|
November 28, 2022
|
Generalized Additive Models with R gam
|
|
1
|
1171
|
November 22, 2022
|
Information, Evidence, and Statistics for critical research appraisal
|
|
17
|
1743
|
November 21, 2022
|
Categorization of continuous outcome and odds ratio
|
|
2
|
570
|
November 8, 2022
|
Interactions and random error
|
|
24
|
9799
|
October 20, 2022
|
Statistics Applied Using Threshold Science Fails to Deliver Progression Toward Truth
|
|
2
|
2661
|
September 23, 2021
|
Quality of remdesivir trials
|
|
54
|
16699
|
October 5, 2022
|
Between Subjects Variance and Within Subjects Variance in ICC
|
|
2
|
901
|
September 25, 2022
|
Could cardiovescular risk nomogram be supirior than the Framingham Risk Score? If so, what could be the reasons?
|
|
0
|
508
|
September 20, 2022
|
Rmsb: Relative Explained Variation of Clustering Variable
|
|
8
|
1738
|
September 7, 2022
|
How to interpret confidence curves?
|
|
3
|
5077
|
September 6, 2022
|
Spurious relation between biomarker and outcome
|
|
11
|
3590
|
September 6, 2022
|
Selection bias or good data management
|
|
6
|
3122
|
August 17, 2022
|
NAs and its meaning in the context of Environment Exposure Analysis
|
|
4
|
1091
|
August 10, 2022
|